by some experimental tumours was recently characterized as a Factor Xactivating enzyme (Curatolo et al., 1979) and it was shown that this thromboplastic activity was clearly different from the Factor VII-dependent activity of most other tissues (Gordon et al., 1975) . Since this activity appeared in serum-free media of fibroblasts after chemical transformation, it was suggested that it might even represent a marker of malignancy (Gordon & Leewis, 1978) .
Factor X-activating activity was instead of tumour cells. The results were expressed as arbitrary units derived from the optical densities generated by 2 7 x ] 05 cells; they are summarized in Table I . As can be seen, only Russell's Viper venom, which is known to be a potent direct activator of Factor X, and tumour cells, produced appreciable amounts of proteolytic activity. There was no statistical difference between the levels of Factor X activator detected in cultured primary and metastatic cells.
After transplantation of freshly suspended 3LL cells derived from a primary tumour into the upper thigh of 12 C57BL mice, 6 animals were treated with the vitamin K antagonist phenprocoumon throughout tumour growth, as previously described . Twelve days after transplantation the primary tumour was surgically removed and the animals were allowed to survive until Day 29. They were then killed and the secondary lung tumours carefully excised. The primary tumours, lung tumours and fragments of abdominal muscle were homogenized and sonicated in normal saline. The protein content of each tissue extract was adjusted to 20 g/l with saline. all extracts were tested for clot-promoting activity using Factor VII-, Factor VIIIand Factor X-deficient human plasma as described by Curatolo et al. (1979) . Table II gives the mean clotting times obtained with different tissue extracts. Considerable thromboplastic activity of all tissues was found when tested in Factor VIII-deficient plasma. In contrast, none of the extracts showed activity when added to Factor X-deficient plasma. Distinct differences however were found when these tissue extracts were tested in Factor VII-deficient plasma; muscle extracts were almost inactive, whereas extracts from primary tumour and lung metastases of untreated animals produced very short clotting times. Extracts from primary and secondary tumours derived from phenprocoumon-treated animals, however, showed considerably less enzyme activity.
From the foregoing it is evident that single-cell cultures from primary and secondary 3LL show a Factor X-activating activity when tested by chromogenic substrates. A similar activity can be found in aqueous extracts of solid tumours 44 and metastases using test plasma with specific clotting factor deficiencies. It is interesting to note that phenprocoumon treatment of the tumour-bearing animals produced a significant decrease of Factor X-activating activity, indicating that this proteolytic enzyme is vitamin-K-dependent. No significant differences between primary and secondary tumours could be established by either method.
The biological significance of the described procoagulant activity in cancer cells is unknown. Previous investigations have shown that warfarin (Poggi et al., 1978) , phenprocoumon and diet-induced vitamin K deficiency (Hilgard, 1977) inhibit primary tumour growth as well as the formation of spontaneous metastases of 3LL. The decreased synthesis of the procoagulant, Factor X-activating activity in anticoagulated and vitamin K-deficient animals indicates that the presence of this enzyme in tumour cells might facilitate the primary and metastatic growth of malignant tumours. This assumption accords with the current concept of the role of fibrin formation in tumour growth (Roos & Dingemans, 1979) and provides an additional rationale for the use of vitamin K antagonists in cancer therapy.
